Semaglutide
Educational content only. This page does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making decisions related to any medication or health intervention.
Overview
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk. It activates the GLP-1 receptor, which plays a role in blood sugar regulation, appetite signaling, and gastric motility. Semaglutide's molecular structure includes modifications — specifically, a fatty acid chain that enables albumin binding — that extend its half-life to approximately seven days, allowing once-weekly administration.
Semaglutide is one of the most extensively studied peptides in clinical medicine, with hundreds of clinical trials conducted globally. It is available in both injectable and oral formulations across multiple approved indications. As of late 2025, Novo Nordisk announced FDA approval of an oral semaglutide formulation for chronic weight management, making it the first oral GLP-1 medication approved for that indication.
Research & Clinical Context
Semaglutide has been evaluated across several major clinical trial programs. The SUSTAIN program studied injectable semaglutide in adults with type 2 diabetes. The STEP program evaluated its effects on weight management in adults with obesity or overweight. The PIONEER program focused on oral semaglutide for type 2 diabetes. The SELECT trial assessed cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease.
These programs have collectively enrolled tens of thousands of participants across dozens of countries, making semaglutide one of the most clinically validated peptides in current use. Research has also explored its effects on kidney outcomes, liver fat, and additional cardiometabolic endpoints.
References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM (2021)
New England Journal of Medicine
- SELECT Cardiovascular Outcomes Trial
ClinicalTrials.gov
Safety & Regulatory Notes
Semaglutide is an FDA-approved prescription medication available under several brand names: Ozempic (injectable, for type 2 diabetes), Wegovy (injectable and oral, for chronic weight management), and Rybelsus (oral, for type 2 diabetes). Each formulation has its own approved indication, dosing, and prescribing information.
As with all prescription medications, semaglutide carries labeled warnings and potential adverse effects described in its prescribing information. Regulatory approval and availability vary internationally. Compounded versions of semaglutide have been the subject of ongoing regulatory and legal action in the United States. Readers should consult a licensed healthcare provider for any decisions about treatment.
How This Fits Into Our Peptide Hub
Semaglutide is the benchmark molecule in GLP-1 research and one of the most commonly searched peptides on our platform. It appears prominently in our price comparison tools, lab-rating features, and head-to-head research summaries alongside tirzepatide and other metabolic peptides.